The human immunodeficiency virus type 1 (HIV-1) has evolved to coordinate its replication with the activation state of the host CD4T cell. To this end, it taps into major host cell signaling pathways and their associated transcription factors. Of these, T-cell activation and the transcription factor NF-kB, respectively, have become the best-studied examples. The past several years have revealed compelling evidence that another transcription factor family involved in T-cell activation, the nuclear factor of activated T cells (NFAT), plays an important role in the regulation of HIV-1. Major advances have been made in our understanding of the interaction of HIV-1 with this intriguing transcription factor. The duplicated NF-kB binding sites in the HIV-1 enhancer surprisingly also bind NFAT proteins and appear to be the most important targets for NFAT transactivation of the HIV-1 long terminal repeat. The crystal structure of NFAT1 bound to one of these duplicated sites was solved recently. Interestingly, it showed that NFAT1 binds to this site as a homodimer and occupies the core of the NF-kB site, suggesting mutually exclusive binding and alternate transactivation by these two factors. NFAT also regulates HIV-1 infection indirectly, as it can relieve a block to reverse transcription in quiescent T cells. In turn, HIV-1, and particularly its Tat and Nef gene products, can upregulate NFAT expression and activity. This reciprocal regulation between virus and transcription factor potentially creates a positive feedback loop, which may facilitate the establishment of early HIV-1 infection and, later, the transition from latent to productive infection. The immunosuppressive drug cyclosporin A (CsA) inhibits NFAT activity and thus represents a potential treatment for HIV-1 infection. Recent small-scale clinical trials have yielded optimistic results, suggesting roles for CsA after organ transplantation in HIV-1 þ individuals and as adjunct treatment in stable early HIV-1 infection.
HIV-1-a transcriptional parasite
Like other viruses, the primate immunodeficiency viruses are intracellular molecular parasites that depend on the host cell biosynthetic machinery to complete their life cycle. Intricate mechanisms have evolved by which viruses tap into various steps of host cell nucleic acid and protein synthesis to coordinate viral replication with specific aspects of the host cell life cycle and to counteract or circumvent the host immune response. Indeed, the interaction between nuclear factor kappa-B (NF-kB) and the human immunodeficiency virus type 1 (HIV-1) enhancer has become a prime example of how a virus usurps a major cellular signaling pathway, presumably to coordinate viral replication with a state of high host cell biosynthetic activity 1 (reviewed in Hiscott et al 2 ) . More recently, several lines of evidence have suggested that another factor involved in T-cell activation, the nuclear factor of activated T cells (NFAT or NF-AT, the former abbreviation being used in this review), plays an important role in the regulation of HIV-1. 3 NFAT participates in T-cell activation through signaling events distinct from NF-kB. Downstream from phospholipase C (PLC), NF-kB is activated via the diacylglycerol/Ca 2 þ /protein kinase C (PKC) pathway, while NFAT regulation follows the IP3/Ca 2 þ /calcineurin pathway. 4 Thus, the interaction with NFAT creates a potentially important additional means for HIV-1 to finetune its life cycle with the activation state of the host cell. The observation that the well-studied immunosuppressive drug cyclosporin A (CsA) can interfere with NFAT activation of HIV-1 gene expression lends additional clinical relevance to this interaction. 3 Thus, the past 10 years have afforded major insights into the various interactions between HIV-1 and this intriguing transcription factor. Among the most significant advances have been the identification of the long terminal repeat (LTR) enhancer sites as the primary target for transcriptional transactivation by NFAT, the findings that NFAT and HIV-1 regulate each other in a reciprocal manner, and last, but not least, the solution of the crystal structure of NFAT1 bound to the HIV-1 enhancer.
NFAT-a versatile transcriptional regulator
Since the discovery of a DNA-binding activity that correlated with induction of the IL-2 gene during Tlymphocyte activation, 5 five NFAT proteins have been isolated. 6 Members of the NFAT family play important roles in cellular differentiation and development in diverse tissues such as the heart, blood vessels, skeletal muscle, skin, adipose tissue, and the peripheral immune system (for reviews see Hogan et al, 6 ,Crabtree and Olson, 7 and Horsley and Pavlath 8 ). NFAT1 (also called NFATp or NFATc2) and NFAT2 (also known as NFATc or NFATc1) are the most abundant family members in the human peripheral immune system, and the best studied in HIV-1 regulation. In primary human T cells, NFAT1 predominates, [9] [10] [11] and NFAT2 levels are increased upon T-cell activation. 12 Interestingly, NFAT1 itself is involved in the induction of NFAT2 via binding to the NFAT2 promoter. 13 The major steps in NFAT regulation in T lymphocytes are represented diagrammatically in Figure 1 . A common property of NFAT proteins, except NFAT5, is that their inactive, phosphorylated form is sequestered in the cytoplasm. Upon an appropriate stimulus (T-cell receptor engagement in the case of T lymphocytes), the Ca 2 þ -calmodulin-dependent phosphatase calcineurin dephosphorylates NFAT proteins and thus exposes their nuclear localization sequences. This leads to their translocation into the nucleus and the subsequent activation of genes carrying NFAT binding sites in their regulatory regions. These genes include Tcell-derived cytokines (eg, IL-2 and IL-4), CD154 (CD40 ligand), and others. 14, 15 Interestingly, in conjunction with cytoplasmic immunophilins, the immunosuppressive drugs CsA and FK506 inhibit the phosphatase activity of calcineurin and thus interfere with NFAT dephosphorylation and nuclear translocation ( Figure 1 ). 16 Nuclear localization of NFAT in T cells is maintained by a persistent Ca 2 þ signal provided by Ca 2 þ release activated channels (CRACs), in the absence of which NFAT is rephosphorylated by specific kinases and rapidly returns to the cytoplasm (Figure 1) . 17, 18 Kinases that oppose calcineurin activity also help maintain NFAT proteins in their phosphorylated, inactive state in resting cells. 6 NFAT proteins recognize purine-rich binding sites whose primary and adjacent sequences determine the composition of NFAT-containing protein/DNA complexes. 19 For instance, the binding sites found in the IL-2 promoter and GM-CSF enhancer consist of abutting NFAT and AP-1 sites and mediate cooperative binding of both factors to these sites (reviewed in Rao et al 15, 19 ). Similarly, adjacent NFAT and GATA binding sites are found in the murine IL-4 and IL-5 enhancers. 19, 20 The NFkB/NFAT binding sites in the HIV-1 enhancer probably bind NFAT monomers or homodimers (see below), although binding of AP-2 to a short spacer between these sites has been described, 21 and other cofactors may exist.
NFAT binding sites in the HIV-1 LTR/ promoter
NFAT protein binding sites are found within three regions of the HIV-1 LTR: in the distal LTR ('upstream Figure 1 Schematic representation of the major steps of NFAT regulation in T lymphocytes. Some intermediate factors have been omitted for the sake of clarity. T-cell receptor (TCR) stimulation activates phospholipase C-g (PLC-g). Generation of inositol-1,4,5-triphosphate (IP3) and its binding to IP3 receptors (IP3r) on the endoplasmic reticulum (ER) results in the release of calcium ions (Ca þ þ ) into the cytoplasm. After depletion of Ca þ þ stores in the ER, increased free Ca þ þ levels are sustained by the entry of extracellular Ca þ þ through Ca þ þ release activated channels (CRACs). Increased Ca þ þ levels activate the calcium-calmodulin-dependent phosphatase calcineurin. The resulting dephosphorylation of NFAT proteins leads to their translocation into the nucleus and the transcription of NFAT-dependent genes. CsA, FK506, and the VIVIT peptide inhibit the activity of calcineurin and the subsequent activation of NFAT proteins. The HIV-1 Tat and Nef proteins induce NFAT activity, most likely by modulating intracellular signaling pathways that activate calcineurin. In addition, Tat may interact with NFAT directly in the nucleus. In the absence of sustained Ca þ þ signaling, rephosphorylation of NFAT proteins by kinases leads to their relocation into the cytoplasm. Sustained high intracellular Ca þ þ levels inhibit these kinases and thus oppose nuclear export and deactivation of NFAT. Other abbreviations: TATA, TATA-box; arrow, start site of transcription. region'), the enhancer region, and in the 5 0 untranslated region (UTR) (Figure 2 ). DNase I footprinting analysis has revealed two binding sites in the distal LTR: a stronger one 5, 22 between base pairs (bp) -216 to -254 and a weaker one 5 between -288 and -303. This latter site is not seen in footprinting assays with recombinant NFAT protein and may represent binding of another factor present in the nuclear extract. Bacterially expressed recombinant NFAT2 strongly protects a region in the enhancer region between -104 and -74, 23 while baculovirus-generated recombinant NFAT2 leaves a somewhat smaller footprint between -99 and -77. 22 This region overlaps with the duplicated NF-kB enhancer sites. In the H9 cell line, a T-cell line chronically infected with HIV-1, in vivo protein occupancy has been demonstrated by DMS-interference footprinting on the stronger one of the two upstream NFAT sites and on the enhancer NFkB/NFAT sites. 24 The monocytic U1 cell line is a model for PMA-inducible cellular and viral transcription. Here, constitutive protein occupancy was found on the higheraffinity upstream NFAT site and at the 5 0 end of the 3 0 enhancer site. Upon induction, interference extended to an additional guanine at the 5 0 end of the 3 0 enhancer site outside of the sequences believed to mediate NFAT binding. 25 Thus, additional factors may play a role in binding to this region.
Gel shift analysis with mutant oligonucleotide probes suggested that NF-kB and NFAT bind with different specificities to overlapping sequences in the enhancer sites. The residues that, when mutated, preferentially interfere with NF-kB binding are located on the coding strand at the 5 0 end and those that preferentially interfere with NFAT binding on the noncoding strand at the 3 0 end of each site (Figure 2) . 22 Both monomeric and dimeric NFAT complexes are observed on probes containing both sites, and the addition of AP-1 does not result in the formation of additional complexes. Interestingly, two NFAT-containing bands of different mobilities are seen on a probe containing a single site, suggesting the possibility of an NFAT dimer bound to a single site.
22
NFAT2 can be immunoprecipitated with Ets1 from normal human T lymphocytes, and this interaction depends on the presence of DNA. However, the existence of an Ets/NFAT/DNA protein complex in vivo has not been demonstrated. 26 By in vitro footprinting and gel shift assays, we have recently identified a binding site for the c-Maf transcription factor just upstream of the enhancer sites. 27 This factor synergizes with NFAT1 to regulate IL-4 production by lymphocytes. 28 We are currently exploring whether it may play a similar role by cooperating with NFAT on the HIV-1 LTR/promoter.
The proximity between the NF-kB and NFAT sites in the HIV-1 enhancer suggests a physical interaction between these two factors on DNA. Surprisingly, few binding studies have addressed this question directly. Gel shift assays with this region, performed under conditions of probe excess, reveal two protein/DNA complexes, one corresponding to NFAT and the other to NF-kB. A ternary complex, presumably containing both factors, is not seen. 22 In competition gel shift analysis, NFAT1 can displace NF-kB p50 from a probe containing a single 3 0 enhancer half-site and the adjacent SP-1 site, The arrows above the sequence denote the NF-kB sites as described in Berkowitz et al 76 and references therein. The arrows below the sequence identify the consensus NFAT binding sequence. The underlined residues designate G-C base pairs which, when mutated, preferentially interfere with NFAT (regular type) or NF-kB (italics) binding. 22 The spacer between the NF-kB/NFAT sites is shaded. The box labeled 'Crystal structure' depicts the residues that form specific hydrogen bonds with NFAT1 in the recently identified crystal structure (adapted from Giffin et al 31 ). The brackets delineate the DNase I footprints of bacterially expressed (bp À104 to -74 23 ) and baculovirusexpressed recombinant NFAT2 (bp À99 to -77 22 ).
NFAT and HIV-1 F Pessler and RQ Cron and, again, a higher order complex containing both factors is not seen. 29 Taken together, the results of these and other binding studies were most consistent with a model where an NFAT monomer or homodimer binds to each enhancer site. Indeed, the crystal structure of the DNA-binding domains of NFAT1 and AP-1 (fos-jun heterodimer) bound to the distal antigen-response receptor element (ARRE) of the IL-2 promoter revealed that the ternary complex consists of one molecule each of NFAT1, AP-1, and the ARRE. 30 The most critical NFAT/ DNA interactions occur by hydrogen bonding with residues G Recently, the crystal structure of NFAT1 bound to one HIV-1 enhancer site was solved. 31 Surprisingly, it revealed that, in contrast to its heterodimeric binding to the ARRE, NFAT1 actually binds to this site as a cooperative homodimer that encircles the DNA like a pair of pliers ( 3 of a nonconsensus site of the coding strand, previously believed to bind NF-kB but not NFAT (Figure 2 ). The duplicated HIV-1 enhancer sites could theoretically bind up to two homodimers, that is, a maximum of four NFAT molecules. This crystal structure also explains why NFAT might outcompete NF-kB for binding to this site, 29 since binding of both factors to the same site seems sterically impossible. Thus, regulation of the HIV-1 enhancer by NFAT and NF-kB may be mutually exclusive.
Lastly, in addition to the upstream and enhancer binding sites, in vivo and in vitro footprinting and gel shift analysis in stimulated Jurkat cells revealed an additional, mitogen-inducible NFAT binding site in the 5 0 UTR between positions þ 165 to þ 181 with respect to the transcription start site. 32, 33 The functional relevance of this site, however, remains unclear.
Regulation of HIV-1 by NFAT
Numerous studies have addressed the potential effects of NFAT proteins on the HIV-1 LTR. These are summarized in Table 1 . Prior indirect evidence that NFAT may regulate HIV-1 transcription came from four unrelated observations: (1) putative NFAT1 binding sites were identified in the HIV-1 LTR by DNase I footprint analysis, 5 (2) an approximately 110 kDa protein of unknown identity was identified using a DNA affinity precipitation assay of the HIV-1 LTR 34 (some NFAT isoforms migrate at approximately 120 kDa), (3) reporter mice transgenic for the HIV-1 LTR 35 exhibited an expression pattern similar to mice expressing the SV40 T antigen under the control of multimerized NFAT binding sites, 36 and (4) CsA, an inhibitor of NFAT, diminished the stimulatory effects of TCR/CD3 signaling on the HIV-1 LTR. 37 The upstream binding region The initial search for effects of NFAT on HIV-1 gene expression focused on the stronger one of the two upstream sites. Surprisingly, mutating or deleting this site had no significant effect on HIV LTR transcription in Jurkat cells 38 and Jurkat-tat cells, a cell line that expresses Tat constitutively. 39 Moreover, removal of this site actually caused a modest increase in viral replication in Jurkat cells 41 and in HIV-1 LTR transcription in primary human CD4T cells. 22 This was consistent with the previous implication of this region as a negative regulatory element.
39,40
The 5 0 UTR binding site Only one study has examined potential functions of this site. 32 Mutating the 5 0 UTR NFAT site alone had no effect on viral replication but decreased basal transcription by 50%. Interestingly, when combined with mutations in other 5 0 UTR protein binding sites, it reduced both viral replication and transcription.
The enhancer binding sites and effects not localized to a specific site In contrast to the mostly negative results obtained in the studies of the upstream binding region, a seminal report by Kinoshita et al 23 has provided evidence that the most important sequences for NFAT regulation are actually located in the HIV-1 enhancer region. Recombinant NFAT2 protects nucleotides -104 to -74 from DNase I digestion, and this binding activity appears in nuclear extracts upon mitogen stimulation. Moreover, in Jurkat thymoma cells, NFAT2 activates the HIV-1 LTR synergistically with Tat, and mutating the 4-bp spacer between the NF-kB/NFAT sites (nucleotides -93 to -90) reduces this effect substantially. Replication of the HIV-1 strain NL4-3 is about three-fold higher in cells stably overexpressing NFAT2. These findings have been corroborated by work from several other laboratories. 
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Importantly, activation of the HIV-1 LTR and stimulation of viral replication by both NFAT1 and 2 have also been verified in primary CD4T lymphocytes. 3, 22 Notably, the immunosuppressive drugs CsA and FK506, both of which interfere with calcineurin activity, as well as a synthetic peptide, VIVIT, 43 which competes for NFAT binding to calcineurin and thereby inhibits the dephosphorylation and nuclear translocation of NFAT1, 2, and 4, all reduce LTR transcription in polyclonally stimulated (PMA þ ionomycin) primary human CD4T cells. 3, 22 Taken together, these results add an additional mechanistic explanation to the previous observation that CsA inhibits HIV-1 replication in culture 37 (reviewed in Cron Clearly, other signaling pathways can modulate this activity, and the importance of intracellular signaling mediated by cell surface molecules other than the TCR has been demonstrated. Crosslinking of CD43 potentiates TCR-dependent activation of HIV-1 transcription and viral replication, and this effect correlates with NFAT and NF-kB binding to the HIV-1 enhancer. 44 Antibodymediated engagement of the TCR/CD3 complex and host-cell attachment by HIV-1 virions ectopically expressing CD86 can synergize to activate NFAT-stimulated HIV-1 LTR transcription. 45 Also, consistent with the previous finding that NFAT levels are upregulated in memory/effector CD4T cells, 11 NFAT1 was recently identified as a major factor responsible for the preferential replication of HIV-1 in CD45RO þ 'memory' T lymphocytes, 46 a potential reservoir of latently infected cells. Interestingly, NFAT-driven HIV-1 LTR transcription Method by which the effect of this site was examined. gs, a specific NFAT complex formed in a gel shift assay; D, the site was deleted; fp, an NFAT footprint was observed on the site; pmut, D, site was inactivated by point mutations or deletion, respectively; ND, not determined.
b Assay used to determine NFAT effect. tt, transient transfection; vr, viral replication; + , decrease; * , increase.
and NFAT1 binding to the HIV-1 enhancer region are potentiated in a CD45-deficient cell line, suggesting that CD45 signaling can inhibit HIV-1 transcription by downregulating NFAT1. 47 In contrast to the above reports, two studies have shown inhibitory or no effects of NFAT proteins at the enhancer sites. In one report, NFAT1 reduced Tat transactivation and had no measurable effect on basal LTR transcription in Jurkat thymoma cells. 29 Likewise, it reduced Rel A (NF-kB)-mediated activation of the HIV-1 LTR. Moreover, in a gel shift assay, recombinant NFAT1 displaced recombinant NF-kB p50 from oligonucleotides containing the 3 0 enhancer site and the adjacent SP-1 site. It was therefore concluded that NFAT1 inhibits transcription by interfering with NF-kB activity at the enhancer NF-kB/NFAT sites. 29 In agreement with this report, but in stark contrast to the deleterious effect reported by Kinoshita et al 23 (see above), mutating the spacer between the NF-kB sites had no effect on basal or Tat-transactivated HIV-1 LTR transcription in phorbol myristil acetate (PMA)-and phytohemagglutinin (PHA)-stimulated Jurkat or CEM cells. 48 These divergent results appear difficult to reconcile. They may relate to the differential activities of signaling pathways and/or NFAT cofactors under the respective experimental conditions. Indeed, depending on the presence or absence of cooperative binding with AP-1, NFAT regulates different sets of cellular genes in the same cell type, 49 and it has been suggested that some NFAT/DNA complexes contain transcriptional repressors. 7 Nevertheless, the bulk of the available evidence suggests that NFAT stimulates HIV-1 transcription. However, one can postulate that the overall effect is actually bimodal, such that under certain conditions NFAT may act as an inhibitor of HIV-1 gene expression. Given the complexity of the HIV-1 life cycle in natural infection, both effects are biologically plausible, although the positive effects likely predominate.
Nontranscriptional effects of NFAT on HIV-1. An equally intriguing aspect of the interaction between NFAT and HIV is that NFAT appears to regulate at least one important nontranscriptional aspect of the viral life cycle. In nondividing primary host cells, blocks to viral replication exist. As a consequence, HIV-1 replicates in PHA-stimulated primary CD4T cells but not in quiescent ones. Primary T cells stably overexpressing NFAT2 permit viral replication in the absence of PHA. 50 This permissiveness is reversible by CsA and FK506 and has been found to be due to relief of a block to reverse transcription, possibly by the induction of one or more cellular cofactors of reverse transcription regulated by NFAT2. 50 Identification of such cofactors is currently in progress (G Nolan, Stanford University, personal communication).
Regulation of NFAT by HIV-1
Given the significant effects of NFAT proteins on HIV-1 gene expression, one might expect that the virus, in turn, has evolved strategies to modulate NFAT activity. Viral strains capable of doing so might experience selective advantages in two ways: (1) enhanced NFAT activity would lead to greater rates of viral replication and (2) reduced NFAT activity would increase the likelihood of the virus remaining in a quiescent state, thus allowing infected cells to escape immune surveillance. Indeed, studies of a different virus, the African swine fever virus, have revealed an intriguing precedent of how a virus can modulate NFAT activity. The viral A238L protein possesses a 14-amino-acid domain with great similarity to an NFAT epitope. This domain inhibits the phosphatase activity of calcineurin and thus interferes with translocation of NFAT2 into the nucleus and the resultant activation of cellular immunomodulatory genes. 51, 52 HIV-1 infection and NFAT. TCR/CD3g expression is downregulated in HIV-1 and -2 infection, possibly contributing to the immune dysfunction in HIV infection. Decreased TCR/CD3g expression in HIV-1-infected cells correlates with the increased binding of NFAT1 and 2 and NF-kB p50 to regulatory sequences in the CD3g gene, suggesting that, in this scenario, these factors might act as repressors of CD3g transcription. It has been postulated that this induction of NFAT activity and the consequent loss of a receptor critical for T-cell signaling would present a means for the virus to downregulate its own gene expression and favor a state of latency. 53 Nef and NFAT. Studies into the mechanism of action of the HIV-1 Nef protein have shown that in transient transfection assays this protein can increase NFAT translocation into the nucleus and the subsequent activation of NFAT-dependent transcription. This effect is TCR independent, mediated by influx of extracellular calcium, and potentiated by the Ras/MAPK pathway. 54 The presence of the HIV-1 Vpr protein further potentiates the increase in NFAT-directed transcription, probably via a regulatory step located further downstream. 55 Cell lines expressing inducible Nef have also revealed increases in NFAT-dependent reporter gene transcription and HIV-1 replication. 56 Tat and NFAT. Another HIV-1 gene product, the Tat protein, has been shown to modulate NFAT activity. An early indication that Tat increases NFAT activity was that Tat enhanced IL-2 promoter activity, and deleting an NFAT binding site between -279 and -263 bp abolished this effect. 57 Subsequently, it was found that Tat enhanced NFAT1-dependent transcription of a reporter construct containing three canonical NFAT binding sites. 29 This effect correlated with the ability of Tat to interact with the transactivation domain of NFAT1. Moreover, in gel shift assays, a ternary complex containing NFAT1 and Tat formed on NFAT binding sites, suggesting that Tat acts by physically recruiting additional NFAT molecules to the promoter. 29 In primary vascular endothelial cells and a Kaposi's sarcoma cell line, Tat alone had only a small effect, but it potentiated NFAT activation by the human herpes virus 8-encoded chemokine homolog vGPCR, an activator of the PI3-K/ Akt signaling pathway. 58 Other mechanisms of NFAT regulation by HIV-1. The MAPK pathway represents another mechanism by which NFAT activity can be increased. HIV-1-infected CD4 T lymphocytes express elevated levels of Grb3-3, an adaptor molecule of the MAPK pathway. This molecule can stimulate NFAT-driven transcription upon CD3/ CD28 engagement, and this effect is suppressed by the MEKK1 kinase or CsA, both of which interfere with NFAT translocation into the nucleus. 59 Genomic and proteomic methods are becoming widely used tools in the study of virus-host interactions. Along these lines, evidence for HIV-1 regulation of NFAT activity has recently been captured by large-scale screens. Since NFAT activity is regulated primarily at the post-transcriptional level, one does not necessarily expect to detect changes in NFAT mRNA levels by DNA microarray and other mRNA-based assays. Nonetheless, three studies of host cell gene expression changes induced by HIV-1 have revealed upregulation of NFAT proteins. In one study, NFAT4 was identified among several genes that were upregulated in HIV-1 IIIB-infected CEM-SS T cells that were relatively protected against undergoing apoptotic cell death. 60 Another study revealed that ectopic expression of HIV-1 Nef led to global changes in cellular transcription reminiscent of those following TCR stimulation, and NFAT2 was among the upregulated genes. 61 Lastly, the binding of HIV-1 gp120 to peripheral blood mononuclear cells and macrophages revealed significant upregulation of NFAT1 protein and NFAT2 mRNA, along with mRNAs and polypeptides corresponding to cytokines, chemokines, kinases, and other transcription factors believed to contribute to productive HIV-1 infection. 62 Keeping in mind that NFAT2 can relieve a block to reverse transcription in quiescent lymphocytes (see above), induction of NFAT activity during the earliest stages of infection might enable the virus to overcome this block.
Taken together, the above results suggest that the African swine fever virus and HIV-1 evolved to modulate NFAT activity in diametrically opposite ways: while the former inhibits NFAT and, potentially, the resultant activation of the host cell, HIV-1 has evolved to primarily upregulate the activity of NFAT proteins. The virus then utilizes this increase in NFAT activity to optimize viral survival and spread in the host in two ways: (1) by creating a host state more permissive to viral infection and (2) by directly increasing viral gene expression and replication.
Thus, NFAT and HIV-1 can upregulate each other. This remarkable reciprocal regulation could potentially create a positive feedback loop, which may facilitate the establishment of early HIV-1 infection and, later, the transition from latent to productive infection. It is tempting to speculate that negative effects of NFAT proteins on HIV-1 gene expression might serve to downregulate this amplification loop under certain circumstances.
Is there a role for NFAT proteins in HIV-2 or SIV? Surprisingly, there are no published reports about potential effects, or lack thereof, of NFAT proteins on HIV-2 or simian immunodeficiency virus (SIV) gene expression or replication. The reason for this apparent neglect may be that the initial work on NFAT and HIV-1 focused on the -254 to -216 upstream binding site, which is not found in HIV-2 or SIV. Moreover, the HIV-2 LTR transcriptional control elements differ fundamentally from those found in HIV-1. 63, 64 In particular, the HIV-2 enhancer possesses only one functional NF-kB site in the enhancer region but contains at least four additional cisinducible elements that bind, among other unidentified factors, the Ets family proteins Elf-1 and Pu.1 (see Clark et al 65 and references therein). In spite of the current lack of experimental evidence, there are hints that a role for NFAT proteins in HIV-2 regulation may exist: (1) CsA inhibits replication of HIV-2 66 and SIV, 67 (2) Elf-1 associates with NFAT in Jurkat cells, 26 and (3) an NFAT binding site, which is identical to the HIV-1 3 0 NF-kB/ NFAT site and could potentially bind an NFAT dimer, is present in the HIV-2 and SIV enhancers.
NFAT-a target for antiretroviral therapy? Given the predominantly stimulatory effect of NFAT on HIV-1, NFAT proteins represent an attractive pharmacologic target for the treatment of HIV-1 infection. Indeed, there has been considerable interest in the use of the immunosuppressive agent CsA for this purpose. At first glance, it would seem counterintuitive to use an immunosuppressive drug for the treatment of an immunodeficiency. However, this interest was motivated by rational observations such as (1) CsA inhibited HIV-1 replication in culture, 68 (2) treatment of HIV-1-infected organ transplant recipients with CsA correlated with a lower risk of progression to AIDS over 5 years (31 vs 90%), 69 and (3) in a nonrandomized pilot study, a subset of non-AIDS HIV-1-infected individuals experienced increased CD4 T-cell numbers while on CsA. 70 Unfortunately, individuals with clinical AIDS did not show a benefit in this study. Consistent with this lack of positive effect in the late stage of HIV-1 infection, eight patients with clinical AIDS deteriorated while on CsA. 71 This led to a lack of interest in treating HIV-1 infection with CsA.
However, in the 10 or more years since these early observations, primary antiretroviral treatment has improved significantly and more HIV-1-infected individuals are in need of organ transplants. Given the aforementioned poor outcomes of CsA use in patients with advanced HIV-1 infection, the focus on CsA in HIV-1 infection has thus shifted to its use in early stable infection and in organ transplantation. Along these lines, the results of three clinical trials were published recently. In one trial, treatment with CsA (2 mg/kg twice a day) in stable early HIV-1 infection (CD4 cell count 4500 Â 10 6 / l, plasma HIV-1 RNA 4600 copies/ml, concurrent treatment with 0-2 antiretroviral drugs) showed no benefit, but a small increase in plasma HIV-1 RNA. 72 In another study, plasma HIV-1 RNA remained undetectable, while CD4 cell counts decreased in four (29%) in a cohort of 14 non-AIDS HIV-1 þ liver and kidney transplant patients (plasma HIV-1 RNA undetectable, CD4 cell count 4100 (liver) or 4200 (kidney)) who were treated with CsA, mycophenolate mofetil, and prednisone. 73 Thus, these reports did not detect a therapeutic benefit but they support the notion that using immunosuppressants for organ transplantation in stable, non-AIDS HIV-1 þ individuals may be relatively safe.
The true benefit of CsA may be as an adjunct therapy along with highly active antiretroviral therapy (HAART). In a nonrandomized pilot study, nine patients on combination therapy of CsA (0.3-0.6 mg/kg for 8 weeks) plus HAART (stavudine, lamivudine, nelfinavir, and saquinavir) had comparable decreases of plasma viral load as expected from HAART, but, in contrast to 29 control patients, had significantly increased CD4 cell counts within 1 week. Surprisingly, this effect persisted until the end of the follow-up period of 64 weeks. 74 Certainly, larger trials will be needed to explore this fascinating phenomenon further. A more extensive trial about CsA as adjunct treatment with HAART is currently in progress (G Rizzardi, University of Lausanne, Switzerland, personal communication).
The development of an NFAT inhibitory peptide by combinatorial peptide selection 43 and the demonstration that its expression in primary T cells decreases HIV-1 transcription 3 are first steps toward the design of anti-HIV-1 drugs that target NFAT specifically. Such NFAT inhibitors promise to be important additions to the pharmacologic treatment of HIV-1 infection. There is, however, a potentially significant caveat. Considering that CsA inhibits transcription factors other than NFAT 22 and that it interferes with several steps of the HIV-1 life cycle other than transcription (reviewed in Cron 3 ), anti-NFAT designer drugs may have fewer side effects but may also be less effective than CsA in interfering with HIV-1 infection.
Outlook
After the initial searches for a role of NFAT through the upstream HIV-1 binding site(s), the past 6 years have redirected the focus onto the duplicated NF-kB/NFAT enhancer sites. Significant advances have been made, but many questions remain unanswered. For instance, what, if any, physical interactions do NFAT proteins undergo with other factors in this region? Do they really bind alone to the enhancer sites or are cofactors involved? How do the various signaling pathways modulate NFAT activity at these sites? Could NFAT have a bimodal effect, for instance by interacting with repressors vs activators? Which factors mediate the nontranscriptional effects of NFAT proteins on HIV-1? The effects of HIV-1 on NFAT activity have thus far been examined almost exclusively by experiments with individual viral gene products, for example, Tat, Nef, and gp120. It will now be important to examine better how the virus alters NFAT activity in natural infection. Moreover, the variation among natural viral isolates in their interactions with NFAT proteins has not been studied systematically. It will also be of great interest to define further the role of NFAT proteins in the HIV-1 life cycle in resting host cells. Could they enable the virus to replicate in these cells at a chronic, low level and thus contribute to the maintenance of the viral reservoir? The coming years also promise to yield important results from larger, controlled clinical studies about the use of CsA in the treatment of HIV-1 infection and organ transplantation in HIV-1 þ individuals. Finally, the development of specific NFAT inhibitors may add to the pharmacologic armamentarium against this deadly virus. The intricate interplay between members of the NFAT family and HIV-1 certainly still has some surprises in store for us.
